Notably, the Apc- and Apc/KRAS-mutant genotypes are not resolved by HCA and PCA, possibly due to the relatively limited number of Apc1638N/+ and Apc1638N/+/KRASV12G tumour samples (n = 5 for each group) employed for the comparative expression profiling analysis, insufficient to highlight the allegedly more subtle differences between benign and malignant CSCs. This evidence concerns the gene KRAS and neoplasm.